CSL Behring s.r.o. is a biopharmaceutical company focused on plasma-derived and recombinant therapies for rare and serious diseases. The product portfolio focus areas include therapies for bleeding disorders, immune deficiencies, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema and alpha-1 antitrypsin deficiency, supported by medical and stakeholder-facing activities in the local market. The geographic scope is the Czech Republic for commercial and medical engagement, operating as part of a global biotechnology organization with international operations and product supply across multiple regions. Key assets include the CSL Behring therapeutic portfolio and the global biotech platform supporting quality, safety and efficacy standards that underpin local market availability. Strategic positioning is as a specialized biotech leader in rare and serious diseases, prioritizing high-quality therapies and sustained medical community engagement to support appropriate use and patient outcomes.
Headquarters
Vyskocilova 1461/2
Prague; The City of Prague;
Postal Code: 14000
Contact Details: Purchase the Csl Behring S.R.O. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service